KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Research & Development (2016 - 2025)

Historic Research & Development for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $267.0 million.

  • Teva Pharmaceutical Industries' Research & Development rose 809.72% to $267.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.0 billion, marking a year-over-year increase of 160.32%. This contributed to the annual value of $1.0 billion for FY2025, which is 150.3% up from last year.
  • As of Q4 2025, Teva Pharmaceutical Industries' Research & Development stood at $267.0 million, which was up 809.72% from $256.0 million recorded in Q3 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Research & Development ranged from a high of $269.0 million in Q2 2024 and a low of $175.0 million during Q3 2022
  • Its 5-year average for Research & Development is $238.6 million, with a median of $243.0 million in 2021.
  • Its Research & Development has fluctuated over the past 5 years, first tumbled by 2117.12% in 2022, then surged by 4457.14% in 2023.
  • Over the past 5 years, Teva Pharmaceutical Industries' Research & Development (Quarter) stood at $244.0 million in 2021, then dropped by 13.93% to $210.0 million in 2022, then rose by 8.1% to $227.0 million in 2023, then grew by 8.81% to $247.0 million in 2024, then grew by 8.1% to $267.0 million in 2025.
  • Its Research & Development stands at $267.0 million for Q4 2025, versus $256.0 million for Q3 2025 and $244.0 million for Q2 2025.